Introduction
This article aims to provide an overview about pharmaceutical pricing and reimbursement policies which European countries, including all EU Member States, apply to promote the use of generic medicines.
In the EU, Member States are free to develop their nationaland regional-pharmaceutical policies in the fi eld of pricing and reimbursement. This is permitted so long as they comply with overall EU provisions, such as the Transparency Directive [1] , e.g. formal procedural aspects such as deadlines or a transparent publication policy. Despite EU harmonisation of marketing authorisation [2] , EU Member States can freely design their pharmaceutical pricing and reimbursement framework, thus opting for more market control and/or promoting competition with regard to generics and other pharmaceutical products.
SPECIAL REPORT some countries, while starting at a lower point, have succeeded in growing their generics markets in recent years.
This article provides: fi rst, an up-to-date picture of the pharmaceutical pricing and reimbursement policies aimed at promoting generics uptake, and second, a discussion of the possible impact of different generics policies on the generics market.
Methods
The author and her team collected information from European countries on generics policies and further measures that have an impact on generics use. This was achieved through direct contact with representatives of the competent public authorities responsible for pharmaceutical pricing and reimbursement.
The author and her team have established good contacts with national offi cials in their role as coordinators of the Pharmaceutical Pricing and Reimbursement Information (PPRI) and the Pharmaceutical Health Information System (PHIS) networks, to which representatives of public authorities belong. PPRI is a networking and information-sharing initiative on pharmaceutical policies which emerged from a European Commission co-funded project under the same name [6, 10] . As of February 2012, PPRI consisted of more than 60 institutions, mainly medicines agencies, ministries of health, and social insurance institutions, from 39 countries. These include all 27 EU Member States, nine further European countries and three non-European countries, plus European and international institutions (European Commission services and agencies, OECD, WHO and World Bank). PHIS was a similar project, broader in scope (including the hospital sector), and involving both public authority staff and hospital pharmacists [11] .
These two projects produced a wealth of information which was considered when designing and drafting this article. Of particular relevance were the PPRI and PHIS Pharma Profi les-national country reports about the pharmaceutical pricing and reimbursement system, written by public authority staff.
After identifying relevant information and policies, data were collected in three steps in the spring of 2011:
Review of country reports produced in PPRI and PHIS 1.
(published PPRI Pharma Profi les [12] , PHIS Pharma Profi les [13] 
Results
The pricing and reimbursement framework is an essential part of a pharmaceutical system. Pharmaceutical pricing and reimbursement policies might be individually designed for different groups of medicines such as innovative medicines, hospital medicines and/or generics.
In terms of pricing, a country may allow free pricing for (some) medicines, i.e. the manufacturer may freely decide on the price, or the authorities can regulate medicine prices according to various price setting methodologies and criteria.
In most European countries manufacturer prices (ex-factory prices) are directly regulated by the State, see Table 1 . However, in a few countries (Cyprus-for imported medicines, Denmark, Finland, Latvia, The Netherlands, Norway, Poland, Sweden and UK) the ex-factory price is indirectly regulated. For example, in Nordic countries, the relevant authorities approve a maximum wholesale price; and in the UK, the Pharmaceutical Pricing Regulation Scheme controls the maximum profi ts of companies.
At the manufacturer level, most countries surveyed control medicine prices only for reimbursable medicines-whose costs are at least partially covered by the national health services or social health insurance [15] . Five countries apply price regulation to all medicines, whereas Denmark and Germany are typically defi ned as 'free pricing countries'. However, even these countries have long-operated price controls on reimbursable off-patent products. Additionally, ongoing reform in Germany has introduced a kind of price control for new medicines [16] .
In summary, a major feature of price control is reimbursement status: reimbursable medicines tend to be subject to state price control whereas non-reimbursable medicines are allowed free pricing. The same applies to reimbursable versus non-reimbursable generics. 
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At the distribution stages (wholesale and pharmacy), the scope of medicines price control is broader: several countries regulate the remuneration for distributors, usually in the form of maximum linear, or regressive, markups. A few other countries only regulate the distribution markup of reimbursable medicines; including generics, see Table 1 .
A common method for determining medicine prices is external price referencing-international price comparison. In 25 of the 29 countries surveyed, competent authorities check medicines prices in other countries when setting and/or negotiating a price. Only Denmark, Sweden and UK do not apply external price referencing, while Germany is just beginning to consider medicine prices elsewhere with regard to certain new medicines [7, 12, 13, 16, 17] .
External price referencing is typically limited, however, to original products [17] . The most common pricing procedure applied to generic medicines is internal price referencing. This is the practice of using the price(s) of identical or similar products in a country when setting a price.
Sixteen countries surveyed required generics-and other 'follower products'-to be priced at a certain percentage lower than the originators-a policy called 'generic price linkage' [3] , see Table 2 . Austria and Estonia, for example, specify that not only the fi rst 'follower', but also all additional followers and the original products are required to lower their price. Since 2005, Norway has used the 'stepped price model' (Trinnprismodellen) to incrementally reduce the price of a medicine according to predefi ned rates, depending on sales volumes. The fi rst reduction occurs after a medicine has lost patent protection [21, 22] .
Key elements of pharmaceutical reimbursement systems are reference price systems and reimbursement listspositive lists for medicines eligible for reimbursement and negative lists specifying products explicitly excluded from reimbursement [15] .
Positive lists are in place in 26 of the surveyed countries (all but Germany, Spain, UK), whereas negative lists are only used in Germany, Hungary, Spain, and UK. Thirdparty payers do not automatically cover the full costs of medicines from the positive lists. Full reimbursement of eligible medicines only occurs in seven countriesAustria, Germany, Ireland, Italy, Malta, The Netherlands, and UK, while elsewhere reimbursement for several medicines is at a lower rate. Criteria for inclusion on a positive list include cost-effectiveness, medical need and therapeutic value-in particular, the relative effectiveness 1 The fi rst follower is required to be priced at least 48% below the originator. The second follower needs to reduce its price by at least 15% from the price from the fi rst follower and the originator by at least 30% within three months after the inclusion of the fi rst follower into reimbursement. The third follower needs to reduce its price by at least 10% from the price from the second follower. At this time all of the products have to reach the price level of the third follower within three months after the inclusion of the third follower. 2 The fi rst follower is required to be priced 30% below the originator. The second follower needs to reduce its price by at least 10% and the next two followers are 5% lower. 3 The follower needs to be priced below the reference price. 4 New regulation since January 2010: the fi rst follower is required to be priced 30% below the originator. The second and third follower need to reduce their price by at least 10% each. 5 Stepped price model (Trinnprismodellen), see explanation in the text. 6 For locally produced medicines. 7 In case of the fi rst follower priced 40% lower than the originator, a faster procedure is offered. 8 Generics to be included into reimbursement are required to be priced at least 30% lower than average price in the reference countries and at least 10% lower than the last bioequivalent generics introduced to the list. 9 A price, which is lower or the same as the highest price within a group of substitutable medicines, is accepted without further investigation. Source: Data provided and updated by staff and offi cial competent authorities involved in the PPRI/PHIS networks, based on references [6, [18] [19] [20] .
in the case of medicines with no new, but added therapeutic value. Another consideration is the estimated budget impact-in central and eastern European countries [7] .
A reference price system is a major policy option for the promotion of generics uptake. This entails clustering identical or similar products into so-called reference groups. Each cluster has a maximum reimbursement amount (reference price) to be covered by the third-party payer. The patient must pay the difference between this reference price and the actual pharmacy retail price, in addition to any other co-payments [15] . Twenty-two of the countries surveyed have a reference price system, 13 of which specify clusters containing medicines with the same active ingredient, see Figure 2 . Most countries defi ne the reference prices around or below the average price of generics, or at the lowest price in the cluster [7, 18, 23] .
In addition to these pricing and reimbursement policies, European countries also employ specifi c demand-side measures to promote the use of generics, targeting prescribers, pharmacists and the public. For example, 23 countries surveyed use generics substitution (mandatory in six countries); while 24 countries use international non-proprietary name (INN) prescribing (mandatory in fi ve countries), see Table 3 . Public information campaigns often focus on generics with the goal of raising awareness and building trust and/or explaining a specifi c generics policy [24] .
Discussion
This survey of generics policies and pharmaceutical pricing and reimbursement shows that European pharmaceutical systems have a strong linkage between pricing and reimbursement, and that some policies are only relevant for reimbursable medicines. As a result, only those generics that are eligible for reimbursement are covered by specifi c regulations such as price control. In contrast, non-reimbursable generics do not fall within the scope of price control. In addition, generics are specifi cally targeted by policies aimed at enhancing their use and saving money-for public payers. Table 4 gives a country-specifi c overview of key policies.
The potential for cost-containment can be seen in the prices of generics which may be set at a lower level (generic price linkage), and via competition from the arrival of new generics on the market. The latter also leads to lower prices of other generics and the originator. Both strategies, partially in parallel, occur in the countries surveyed, and add to a growing body of reports about different generics pricing policies including mixed approaches [25] .
Policymakers tend to take a broad view of generics. Several countries promote the use of not just generics but also 'nonexpensive' products. These may include copyproducts, parallel imported medicines, for example, in Denmark or Germany [18] , and even less expensive original products (as in Belgium [26] ). Countries vary as to the necessary price difference between a generic medicine, or other follower products, and the originator. Questions may arise over whether higher price differences are possible, and by how much, and whether lower prices might be achieved for generics through policies other than the generic price linkage. Countries, which do not explicitly require generics to be priced at a certain percentage lower still report considerable price differences, for example, The Netherlands [18, 28] and Slovakia [27] . This they attribute to market competition, for instance, supported by tendering mechanisms in the outpatient sector [29] . In addition, according to a literature review, while generic price linkages and price regulation did succeed in lowering generic medicine prices to a certain point, there were SPECIAL REPORT indications for a higher potential for savings which might be triggered by free-price competition in the generics market [30] .
A widely-used approach to promote generics in European countries is the introduction of demand-side measures, notably generics substitution and INN prescribing. Ten countries in the survey combined these two measures. A few countries have either one or other in place (six countries with INN prescribing but no generics substitution, three countries with generics substitution but no INN prescribing, see Tables 3 and 4 . The choice of just one of the policies could be due to its appearing suffi cient for achieving the expected results. In the UK, with a high rate of INN prescribing and a comparatively high generics market share, the government decided against the introduction of generics substitution planned for 2010 following a public consultation [31] ).
A common combination, however, is generics substitution or INN prescribing together with a reference price system-seen in 20 countries. In combination, these two tools appear to positively infl uence each other [6] . Among the countries surveyed, only one country (Austria) lacks all three of the aforementioned policies. Its generics market shares are comparably low, but are now on the increase following the introduction of a generics price linkage policy [32] .
It is important to highlight not only the quantity of measures, but also the quality of their implementation. Stringent implementation of a few measures can produce the desired effects. For instance, Sweden produced a high generics market share even after abolishing the reference price system, perhaps because another system of clustering similar medicines already existed, as well as mandatory generics substitution [6, 33, 34] and discussion/references below. Norway's stepped price model, introduced in 2005, has increased the market share for generics from 31.8% of the volume of the outpatient market in 2005 to 38.4% in 2007, see Figure 1 . Norway has thus 'ensured that prices for generics have fallen' [22] . But in the context of Norway's overall pricing policies, the introduction of a pricing regime linked to prices in other European countries, and the design of their external price referencing, had a moderating effect on the Norwegian price level in general [35, 36] .
The level of enforcement also affects the success of new measures to promote generics use and control prices [6, 18] 
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This mandatory implementation of a policy has proved successful at increasing generics uptake, for example, in Sweden [6, 37, 38] .
Besides mandatory enforcement (possibly accompanied by fi nancial sanctions), incentives for stakeholders can also be an issue. In The Netherlands, a fi nancial incentive was in place for years allowing pharmacists to retain one third of the difference between the price of the medicine and the reference price if they dispensed a medicine below the reference price [39] . This incentive appears to have contributed to an increase in the generics market share, but interestingly, after the abolition of the measure in 2005, the generics substitution rate continued to stay at a high level and even rose (42% in volume of total market in 2005, 56% in 2009, see Figure 1 ). Some experts feel that the continuing high substitution rate is attributable to a positive attitude that has developed among Dutch pharmacists [18] . Another example is a pilot project in Austria, in which patients of a small sickness fund were charged a lower prescription fee if they obtained a generic instead of a brand-name medication. As a result, the patients asked for the generics and the share of generics prescriptions rose [40] .
These examples suggest that in addition to formal mechanisms, such as punishing sanctions or encouraging incentives, a 'generics culture', i.e. a positive attitude and trust in generics (and biosimilars), may contribute signifi cantly to an increased use of generics. We recommend the development of such a culture, using strategies that target all stakeholders, including patients.
Finally, the organisation of a reference price system is another trigger for generics uptake. Twenty-two of the European countries surveyed have a reference price system; thirteen of these organise the reference groups at the Anatomic Therapeutic Chemical classifi cation level 5, in other words, clustering of medicines with the same active ingredient, see Figure 2 . This is the easiest way to manage the system and probably an appropriate starting point when introducing such a policy. However, care should be taken over the defi nition of a cluster: a very narrow cluster can result in some patients re-allocating their demand away from the reference group to an alternative non-patent medicine, with the consequent loss of potential savings [18, 23, 39, 41] . Such 're-allocation of demand' has been observed, to some extent, in a few European countries, for example, France and Italy [42] .
Another relevant parameter in the design of a reference price system is the fi xed reimbursement amount, i.e. the so-called reference price. In mature high-volume generics markets such as in Poland, a higher reimbursement amount might be advisable for a brief period, to provide incentives for generics manufacturers to enter the market [43] . A lower reference price generally results in higher savings. In this respect, Portugal, which initially set the reference price at that of the highest priced generics in the reference group [44, 45] , decided in 2010 to reset the price to the average of the fi ve lowest priced medicines [8] . In future it will be useful to examine the impact of this decision on the generics market shares. Further, in fi ve other European countries: Belgium, Estonia, Latvia, Lithuania, Spain; the methodology regarding the calculation of the reference price was changed in 2010 and 2011 [8] , apparently for cost-containment reasons, because these countries were strongly hit by the global fi nancial crisis.
Conclusion
European pharmaceutical systems use several different types of pricing and reimbursement policies for medicines including reimbursable medicines. Generics, if deemed reimbursable, are subject to the same policies. In addition, many countries have implemented specifi c measures to promote generics uptake, including demand-side measures targeting prescribers, pharmacists and, less frequently, patients. Usually, a mix of policies is employed. The design of these measures can signifi cantly infl uence generics uptake and the degree of public savings. However, the diffi culties in enforcing these measures should be addressed. Creating a 'generics culture', i.e. an environment which is positive towards generics, appears to support other policy measures.
For patients
Several European countries aim to increase generics uptake, this allows offering medicines at lower prices for the sake of patients who have to pay out-of-pocket and/or to co-pay. In the case of publicly funded medicines it also offers savings for the healthcare system and thus provides fi nancial headroom for funding innovation, therefore, increasing both accessibility and affordability to patients. Evidence about generics policies helps not only the policymakers to reach their aims but also the patients benefi ting from improved accessibility and affordability.
